Pharma lobbies to exempt rare disease drugs from Colorado price controls, highlighting systemic inequities in healthcare access
Original framing: “STAT+: Pharma companies and patient groups seek to exempt orphan drugs from Colorado pricing limits” — STAT News
The current push to exempt orphan drugs from price caps mirrors historical patterns of pharmaceutical lobbying in the U.S., such as the 1980s Orphan Drug Act, which was designed to incentivize rare disease research but has since been exploited for profit. Similar dynamics occurred with the HIV/AIDS crisis, where pricing was initially resisted despite public health needs.
The push to exempt orphan drugs from Colorado's pricing caps is not just a policy debate—it is a symptom of a larger systemic failure in U.S. healthcare, where corporate interests dominate public health priorities.
This dynamic is rooted in historical patterns of regulatory capture and lobbying, which have allowed pharmaceutical companies to maintain monopolistic pricing structures. Cross-culturally, alternative models exist where public health is prioritized without stifling innovation. By integrating scientific evidence, patient voices, and global health equity into policy, the U.S. could move toward a more balanced and ethical approach to drug pricing. The future of healthcare depends on dismantling the power imbalances that currently favor profit over people.